Physician profile
Justin M Brown
NPI 1033234562
$13,571.15
in general payments reported to CMS, 2019-2025
9 companies · $2,477 in 2025
The $2,477 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,321 · 2020: $1,162 · 2021: $1,447 · 2022: $1,929 · 2023: $2,191 · 2024: $2,044 · 2025: $2,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $6,445 · Food and Beverage: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $6,445.00 |
| Food and Beverage | $267.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuvasive, INC. | $6,142.54 | 2020-2023 | Nvm5 |
| Globus Medical, INC. | $4,504.24 | 2024-2025 | Nvm5 |
| Alphatec Spine, INC | $2,000.00 | 2019 | |
| Stryker Corporation | $250.60 | 2023 | Yukon Oct Spinal System, Airo, Ozark Cervical Plate System |
| Axogen | $233.46 | 2022 | |
| Checkpoint Surgical, INC | $213.32 | 2019 | |
| Boston Scientific Corporation | $107.43 | 2019 | |
| Integra Lifesciences Corporation | $102.94 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $16.62 | 2025 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.